TUDRIQEV Approval Represents a Key Regulatory Achievement in Advanced Melanoma Replimune has reached an important milestone in oncology with the accelerated approval of tudriqev (vusolimogene oderparepvec-wtpg), previously identified as RP1. The FDA authorized TUDRIQEV in combination with Bristol Myers Squibb’s OPDIVO (nivolumab) on August 6, 2026, for adults with unresectable, advanced...